Medexus Pharmaceuticals (CVE:MDP) Shares Down 4.9%

Medexus Pharmaceuticals Inc. (CVE:MDPGet Rating)’s stock price dropped 4.9% during trading on Wednesday . The company traded as low as C$7.70 and last traded at C$7.75. Approximately 40,981 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 68,619 shares. The stock had previously closed at C$8.15.

Separately, Raymond James lifted their target price on shares of Medexus Pharmaceuticals from C$5.50 to C$5.75 and gave the company an “outperform” rating in a research note on Wednesday, March 2nd.

The stock has a market cap of C$148.54 million and a P/E ratio of -4.28. The business’s 50 day simple moving average is C$7.75 and its 200 day simple moving average is C$7.75. The company has a debt-to-equity ratio of 1,174.36, a current ratio of 1.19 and a quick ratio of 0.74.

About Medexus Pharmaceuticals (CVE:MDP)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.